Alterity Therapeutics (PRAN) Competitors

Cybin (NYSE:CYBN) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Does the media refer more to CYBN or PRAN?

In the previous week, Cybin had 11 more articles in the media than Alterity Therapeutics. MarketBeat recorded 14 mentions for Cybin and 3 mentions for Alterity Therapeutics. Cybin's average media sentiment score of 0.09 beat Alterity Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate CYBN or PRAN?

Cybin presently has a consensus target price of $85.00, indicating a potential upside of 1,128.32%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Alterity Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals and insiders have more ownership in CYBN or PRAN?

17.9% of Cybin shares are owned by institutional investors. Comparatively, 3.6% of Alterity Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more risk & volatility, CYBN or PRAN?

Cybin has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Is CYBN or PRAN more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-37.58%	-36.59%
Alterity Therapeutics	N/A	N/A	N/A

Which has better valuation & earnings, CYBN or PRAN?

Alterity Therapeutics has higher revenue and earnings than Cybin. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$57.88M	-$4.60	-1.50
Alterity Therapeutics	$150K	298.45	-$6.40M	-$0.70	-7.19

Summary

Cybin beats Alterity Therapeutics on 8 of the 15 factors compared between the two stocks.